Personalis (NASDAQ:PSNL) Receives “Buy” Rating from Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Personalis (NASDAQ:PSNL) in a research note published on Wednesday,Benzinga reports. They currently have a $7.25 price target on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Personalis in a research report on Wednesday.

Personalis Stock Performance

Shares of PSNL opened at $5.60 on Wednesday. Personalis has a fifty-two week low of $1.12 and a fifty-two week high of $7.20. The firm has a 50-day simple moving average of $4.69 and a 200-day simple moving average of $4.32. The company has a market capitalization of $395.63 million, a price-to-earnings ratio of -3.33 and a beta of 1.75.

Personalis (NASDAQ:PSNL) last announced its earnings results on Wednesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.31). Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The company had revenue of $25.71 million during the quarter, compared to analysts’ expectations of $20.67 million. During the same quarter last year, the business posted ($0.51) earnings per share. Equities research analysts forecast that Personalis will post -1.41 EPS for the current year.

Institutional Trading of Personalis

Hedge funds have recently modified their holdings of the business. ARK Investment Management LLC grew its holdings in Personalis by 11.4% during the third quarter. ARK Investment Management LLC now owns 7,085,523 shares of the company’s stock worth $38,120,000 after acquiring an additional 723,637 shares during the period. Walleye Capital LLC purchased a new stake in shares of Personalis during the 3rd quarter worth $897,000. Jane Street Group LLC grew its stake in shares of Personalis by 154.3% during the 3rd quarter. Jane Street Group LLC now owns 164,281 shares of the company’s stock worth $884,000 after purchasing an additional 99,671 shares during the period. Geode Capital Management LLC increased its holdings in shares of Personalis by 20.0% in the 3rd quarter. Geode Capital Management LLC now owns 498,470 shares of the company’s stock valued at $2,683,000 after purchasing an additional 83,068 shares in the last quarter. Finally, Centiva Capital LP acquired a new stake in shares of Personalis in the third quarter valued at about $380,000. 61.91% of the stock is owned by institutional investors and hedge funds.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.